MYP_057080
Basic Information
Avelumab
Anticancer
Immunology Immune modulation Immunomodulatory activity
Immunology Immunomodulation Immuno-oncology
Standard
450 amino acids
C2194H3418N578O670S16
Standard
Sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Physicochemical Analysis
49125.12 Da
8.60
6.54
5.63
0.0145
-0.31
0.50
0.04
42.55
74.18
0.0911
72310.00
72935.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0245248 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Mus musculus [Animal]
Monoclonal antibody
9606;10090
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer Immunomodulatory Immuno-oncology
The terminal half-life is approximately 6.1 days in patients receiving 10 mg/kg.